BCL2 and acute myeloid leukemia: We tested the BCL-2 inhibitor venetoclax in a panel of three KMT2A-r AML cell lines, namely, t (6; 11) SHI-1 and t (9; 11) NOMO-1 and THP1 and in a non-KMT2A cell line, HL60.